N-Acetyl Semax Amidate: Mechanism of Action

Introduction

N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂) belongs to a class of synthetic heptapeptides derived from the ACTH(4–10) fragment, sharing the core sequence of Semax with dual N-terminal acetylation and C-terminal amidation. The published pharmacological framework for this compound class is grounded primarily in Semax and, to a lesser extent, in N-acetyl Semax. The following sections synthesize that literature, attributing findings to the specific compound examined in each cited source, and represent a rich body of research spanning in vitro receptor characterization, rodent neurochemistry, and genome-wide gene expression analysis [1, 2].

Receptor Targets and Pharmacological Pathway

Semax and its ACTH(4–10)-derived analogs interact with the melanocortin receptor system, a family of five G-protein-coupled receptors (MC1R–MC5R) encoded by distinct genes and expressed across brain, immune, and peripheral tissues. ACTH(4–10) itself is considered a minimal melanocortin pharmacophore — the shortest fragment capable of receptor engagement while lacking the steroidogenic potency of full-length ACTH [1].

Dolotov and colleagues (2006) reported that tritium-labeled Semax displayed specific, saturable binding in membrane preparations from rat basal forebrain, with a dissociation constant (KD) of approximately 2.4 nM and a binding maximum (Bmax) of 33.5 fmol/mg protein. The authors noted that this binding pattern was consistent with engagement of melanocortin receptor sites. The same publication reported that intranasal Semax produced a rapid, region-selective rise in BDNF (brain-derived neurotrophic factor) protein levels in the rat basal forebrain but not in the cerebellum, a finding the investigators interpreted as indicating anatomically localized receptor engagement rather than a systemic effect [3].

N-terminal acetylation has been documented to alter the metal-coordination geometry of the Semax peptide while leaving other interactions intact. Magrì and colleagues (2016) demonstrated that N-acetyl Semax formed a CuN3O chromophore at physiological pH, distinct from the CuN4 chromophore of unmodified Semax, and observed that the copper-mediated cytoprotective activity of unmodified Semax in SH-SY5Y neuroblastoma cells was specifically attributable to the free N-terminal amine required for copper chelation. This finding clarified an important mechanistic distinction between the acetylated and unacetylated forms while informing how other receptor interactions may be preserved [2].

Reported Molecular Interactions

Neurotrophin Gene and Protein Expression

Among the most studied interactions of the Semax peptide family is its relationship to BDNF and NGF (nerve growth factor) signaling in rodent brain tissue. Dolotov and colleagues (2003) reported that a single administration of Semax to rats produced a measurable rise in BDNF mRNA across multiple brain regions in vivo, including hippocampus, frontal cortex, and hypothalamus [4].

Dolotov and colleagues (2006) further characterized this response, reporting a 1.4-fold increase in BDNF protein in the rat hippocampus, a 3-fold increase in BDNF exon III mRNA, and a 1.6-fold increase in TrkB tyrosine phosphorylation — reflecting activation of the primary high-affinity BDNF receptor — following Semax administration [3].

Shadrina, Kolomin and colleagues (2010) examined the time course of both BDNF and NGF gene expression across rat hippocampus, frontal cortex, and retina using real-time PCR at six time points from 20 minutes to 24 hours. They characterized the overall pattern as multidirectional and region-dependent: frontal cortex expression was elevated at 20 minutes, while retinal BDNF expression was significantly elevated at 90 minutes. The authors described these dynamics as reflecting region-specific neurotrophin regulation under Semax rather than a uniform directional change, informing subsequent mechanistic hypotheses about the compound's localized CNS effects [5].

Neurotrophin Receptor Transcription Under Ischemic Conditions

Dmitrieva, Povarova, Skvortsova, Myasoedov and colleagues (2010) reported that Semax activated transcription of BDNF, TrkC, and TrkA genes at three hours following permanent middle cerebral artery occlusion in rats, with NGF transcription elevated at 24 and 72 hours. The C-terminal tripeptide Pro-Gly-Pro, a metabolite of Semax degradation, showed partially overlapping but distinct effects on the same neurotrophin receptor genes — a finding that established the intact Semax sequence and its metabolite as pharmacologically non-equivalent in their neurotrophin gene effects under ischemic conditions [6].

Serotonergic and Dopaminergic Interactions

Kolomin and colleagues (2006) measured neurochemical parameters in the striata of rats following Semax administration, reporting a 25% increase in the tissue content of 5-hydroxyindoleacetic acid (5-HIAA, a serotonin metabolite) at two hours, with extracellular striatal 5-HIAA rising to approximately 180% of baseline within one to four hours. In a co-administration paradigm, Semax administered prior to d-amphetamine was reported to augment amphetamine's effect on extracellular dopamine, consistent with a modulatory influence on dopaminergic responsiveness under pharmacological stimulation [7].

Cholinergic System Interactions

Grivennikov, Dolotov, Zolotarev, Andreeva, Myasoedov and colleagues (2008) examined the effect of Semax on rat basal forebrain cholinergic neurons in dissociated cell culture. They reported that Semax at 100 nM was associated with approximately 1.5–1.7-fold greater cholinergic neuron survival compared to untreated controls and with elevated choline acetyltransferase (ChAT) activity. The effect was selective for the cholinergic phenotype, with GABA-ergic and total neuron-specific enolase-positive neurons unaffected at the tested concentration [8].

Calcium Signaling

A 2025 study published in the Bulletin of Experimental Biology and Medicine examined the effect of Semax on intracellular calcium dynamics in rat brain neurons using fluorescent imaging. Semax at 1 µM was reported to significantly increase the frequency of spontaneous calcium oscillations in CA1 pyramidal layer cells of the rat hippocampus. The investigators noted no significant effect on proton-stimulated calcium entry through acid-sensing ion channels in cerebellar granule cells, and interpreted this regional selectivity as indicating that the neuroprotective mechanism of Semax in hippocampal tissue likely operates through a pathway distinct from ASIC inhibition in cerebellar neurons [9].

Downstream Effects

Genome-wide transcriptional analysis of rat brain tissue following permanent middle cerebral artery occlusion, reported by Medvedeva and colleagues (2014) in BMC Genomics, characterized Semax-associated changes across immune-response and vascular-system gene networks. The study described predominantly altered expression of immune genes 24 hours after occlusion, including immunoglobulin-encoding and chemokine-encoding transcripts. Vascular-system genes associated with endothelial migration and vasculogenesis also showed altered expression at three and 24 hours [10].

Sudarkina, Filippenkov and colleagues (2021) employed mass spectrometry-based proteomics to characterize protein expression changes in rat brain following ischemia-reperfusion, with and without Semax treatment. They identified over 40 proteins significantly associated with Semax exposure, with patterns the authors described as consistent with changes in apoptotic and inflammatory signaling proteins and in synaptic plasticity-associated proteins at the proteome level [11].

Active Research Frontier

Mechanistic characterization of the Semax peptide family continues to develop across several fronts. The specific melanocortin receptor subtype(s) — MC1R through MC5R — responsible for the neurotrophin and neurotransmitter effects attributed to Semax represent a question that receptor subtype-selective antagonist studies are positioned to resolve. Separately, the dual terminal modification of N-Acetyl Semax Amidate — combining N-acetylation with C-terminal amidation — creates a compound with altered charge state, hydrophilicity, and enzymatic stability relative to both Semax and mono-acetylated N-acetyl Semax, making it a well-defined candidate for comparative receptor pharmacology studies. The 2020s literature, including the 2025 calcium dynamics paper and the Alzheimer-model studies from Radchenko and colleagues, reflects an expanding scope of investigation within this peptide class. A summary of the primary published studies informing this mechanistic picture is available in the N-Acetyl Semax Amidate published research article. Research-grade N-Acetyl Semax Amidate from SpartaLabs is batch-verified by independent mass spectrometry and HPLC analysis.

References

1. Koroleva SV, Myasoedov NF. Semax as a universal drug for therapy and research. Biol Bull. 2018;45(6):589–600. DOI: 10.1134/S1062359018060055

2. Magrì A, Munzone A, Peana M, Medici S, Zoroddu MA, Hansson Ö, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016;164:59–69. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013

3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82–86. DOI: 10.1111/j.1471-4159.2006.03658.x

4. Dolotov OV, Seredenina TS, Levitskaia NG, Rozyczka J, Engele J, Andreeva LA, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003;391:293–295. DOI: 10.1023/A:1025177812262

5. Shadrina MI, Kolomin TA, Agapova TY, Dolotov OV, Grivennikov IA, Slominsky PA, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30–35. PMID: 19662538. DOI: 10.1007/s12031-009-9270-z

6. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71–79. PMID: 19633950. DOI: 10.1007/s10571-009-9432-0

7. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2006;31(3):285–292. PMID: 16362768. DOI: 10.1007/s11064-005-8826-8

8. Grivennikov IA, Dolotov OV, Zolotarev YA, Andreeva LA, Myasoedov NF, Leacher L, et al. Effects of behaviorally active ACTH(4-10) analogue — Semax on rat basal forebrain cholinergic neurons. Restor Neurol Neurosci. 2008;26(1):35–43. PMID: 18431004

9. Korolev DO, Zolotarev YA, Grivennikov IA. The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bull Exp Biol Med. 2025. DOI: 10.1007/s10517-025-06501-z

10. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661604. DOI: 10.1186/1471-2164-15-228

11. Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Gubsky LV, Limborska SA, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion. Int J Mol Sci. 2021;22(12):6179. PMID: 34201112. DOI: 10.3390/ijms22126179